S 64315
Myelodysplastic Syndrome (MDS)
Institut de Recherches Internationales ServierSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
315 Active assets in the Myelodysplastic Syndrome (MDS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
Anti-Thymoglobulin, Rabbit Peking University First Hospital | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
S 64315 is also rated in:
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaDormant
CC
Indicative ·
46 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →